Evofem Biosciences, Inc. (EVFM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 3.5M 7M 10.5M Q3 '19: 0 Q4 '19: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: 278K Q4 '20: 168K Q1 '21: 1.1M Q2 '21: 1.9M Q3 '21: 1.7M Q4 '21: 3.6M Q1 '22: 4.3M Q2 '22: 6M Q3 '22: 6.4M Q4 '22: 181K Q1 '23: 5.8M Q2 '23: 2.5M Q3 '23: 5.1M Q4 '23: 4.8M Q1 '24: 3.6M Q2 '24: 4.2M Q3 '24: 4.5M Q4 '24: 7.1M Q1 '25: 845K Q2 '25: 4.8M Q3 '25: 5M Q4 '25: 9.6M Q1 '26: 899K Q2 '26: 2.6M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Gross Profit Quarterly

-2.5M 0 2.5M 5M 7.5M Q3 '19: 0 Q4 '19: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: -39K Q4 '20: 17K Q1 '21: 599K Q2 '21: 1M Q3 '21: 757K Q4 '21: 1.8M Q1 '22: 3.2M Q2 '22: 4.7M Q3 '22: 4.7M Q4 '22: -203K Q1 '23: 4.4M Q2 '23: 165K Q3 '23: 3.2M Q4 '23: 3.9M Q1 '24: 2.9M Q2 '24: 3.4M Q3 '24: 3.6M Q4 '24: 5.6M Q1 '25: 480K Q2 '25: 4.1M Q3 '25: 4M Q4 '25: 7M Q1 '26: 489K Q2 '26: 2.1M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '16: -1.9M Q4 '16: -2M Q1 '17: -4.9M Q2 '17: -6.4M Q3 '17: -9.1M Q4 '17: -15.3M Q1 '18: -21M Q2 '18: -23.2M Q3 '18: -18.4M Q4 '18: -15M Q1 '19: -13.6M Q2 '19: -11.9M Q3 '19: -14.3M Q4 '19: -12.9M Q1 '20: -19.2M Q2 '20: -22.4M Q3 '20: -26.2M Q4 '20: -35.9M Q1 '21: -44.9M Q2 '21: -41.1M Q3 '21: -43.4M Q4 '21: -37.4M Q1 '22: -28.9M Q2 '22: -24.4M Q3 '22: -18.7M Q4 '22: -12.1M Q1 '23: -3.6M Q2 '23: -7.3M Q3 '23: -3.6M Q4 '23: -3.4M Q1 '24: -2.8M Q2 '24: -1.4M Q3 '24: -2.4M Q4 '24: -1M Q1 '25: 327K Q2 '25: -1.3M Q3 '25: 951K Q4 '25: 3.3M Q1 '26: -4.6M Q2 '26: -2.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '16: -2.4M Q4 '16: -14.2M Q1 '17: -5.3M Q2 '17: -6.5M Q3 '17: -74M Q4 '17: -19.5M Q1 '18: -69.1M Q2 '18: -23.2M Q3 '18: -18.4M Q4 '18: -15M Q1 '19: -18.1M Q2 '19: -35.5M Q3 '19: -13.8M Q4 '19: -12.7M Q1 '20: -19.1M Q2 '20: -52.7M Q3 '20: -29.9M Q4 '20: -40.6M Q1 '21: -46.2M Q2 '21: -33.4M Q3 '21: -74.1M Q4 '21: -51.6M Q1 '22: -31.9M Q2 '22: -126M Q3 '22: 89.5M Q4 '22: -8.3M Q1 '23: -2.4M Q2 '23: -8.6M Q3 '23: 66M Q4 '23: -2.1M Q1 '24: -4.8M Q2 '24: 1.4M Q3 '24: -2.4M Q4 '24: -3M Q1 '25: 956K Q2 '25: -1.8M Q3 '25: -1.6M Q4 '25: 2.8M Q1 '26: -5.5M Q2 '26: -11M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 900K 1.8M 2.7M Q3 '19: 0 Q4 '19: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: 317K Q4 '20: 151K Q1 '21: 506K Q2 '21: 839K Q3 '21: 955K Q4 '21: 1.8M Q1 '22: 1.1M Q2 '22: 1.3M Q3 '22: 1.7M Q4 '22: 384K Q1 '23: 1.4M Q2 '23: 2.3M Q3 '23: 1.9M Q4 '23: 954K Q1 '24: 684K Q2 '24: 769K Q3 '24: 869K Q4 '24: 1.5M Q1 '25: 365K Q2 '25: 755K Q3 '25: 905K Q4 '25: 2.6M Q1 '26: 410K Q2 '26: 511K Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '16: -3.1M Q4 '16: -2.9M Q1 '17: -6.1M Q2 '17: -3.5M Q3 '17: 3.7M Q4 '17: -13.4M Q1 '18: -18.1M Q2 '18: -19.2M Q3 '18: -8.9M Q4 '18: -10.2M Q1 '19: -7.7M Q2 '19: -19.5M Q3 '19: -14.4M Q4 '19: -13.4M Q1 '20: -14.9M Q2 '20: -15.1M Q3 '20: -35.8M Q4 '20: -39.1M Q1 '21: -34.5M Q2 '21: -53.6M Q3 '21: -37.4M Q4 '21: -21.3M Q1 '22: -20.9M Q2 '22: -26.7M Q3 '22: -16.3M Q4 '22: -6.5M Q1 '23: -4.9M Q2 '23: -1.5M Q3 '23: -2.4M Q4 '23: -170K Q1 '24: 123K Q2 '24: -1.1M Q3 '24: -459K Q4 '24: -2.4M Q1 '25: 560K Q2 '25: -2.9M Q3 '25: 336K Q4 '25: 31K Q1 '26: 2.3M Q2 '26: -3.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q1 '14: -2.8M Q2 '14: -1.9M Q3 '14: -1.7M Q4 '14: -3.2M Q1 '15: -5M Q2 '15: -7.8M Q3 '15: -11.7M Q4 '15: -13.6M Q4 '17: -13.4M Q4 '18: -10.3M Q4 '19: -13.6M Q1 '20: -15M Q2 '20: -15.5M Q3 '20: -36.1M Q4 '20: -40.5M Q1 '21: -35.4M Q2 '21: -54.9M Q3 '21: -38M Q4 '21: -21.3M Q1 '22: -21M Q2 '22: -26.8M Q3 '22: -16.4M Q4 '22: -6.6M Q1 '23: -4.9M Q2 '23: -1.5M Q3 '23: -2.4M Q4 '23: -170K Q1 '24: 109K Q2 '24: -1.1M Q3 '24: -459K Q4 '24: -2.4M Q3 '25: 336K Q4 '25: 28K Q1 '26: 2.3M Q2 '26: -3.1M Q1 '15 Q4 '18 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 2.5B 5B 7.5B Q2 '20: 57.7M Q3 '20: 81.2M Q1 '21: 5.5M Q2 '21: 8.3M Q3 '21: 10.3M Q1 '22: 11.1M Q2 '22: 217K Q3 '22: 4.4M Q1 '23: 1.3M Q2 '23: 1.6M Q3 '23: 730M Q1 '24: 31.2M Q2 '24: 1.6B Q3 '24: 96.5M Q1 '25: 6.2B Q2 '25: 120.5M Q3 '25: 119.6M Q1 '26: 133.2M Q2 '26: 137.3M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-750.00 -500.00 -250.00 0.00 250.00 500.00 750.00 Q2 '15: 0.58 Q3 '15: 6.63 Q4 '15: -18.90 Q1 '16: -18.84 Q2 '16: -18.34 Q3 '16: -17.25 Q4 '16: -0.99 Q1 '17: -3.69 Q2 '17: -7.28 Q3 '17: -45.42 Q4 '17: -55.78 Q1 '18: -57.26 Q2 '18: -54.59 Q3 '18: -16.99 Q4 '18: -7.02 Q1 '19: -3.07 Q2 '19: -2.93 Q3 '19: -2.52 Q4 '19: -2.21 Q1 '20: -1.94 Q2 '20: -1.88 Q3 '20: -1.95 Q4 '20: -2.17 Q1 '21: -10.23 Q2 '21: -13.33 Q3 '21: -20.16 Q4 '21: -24.21 Q1 '22: -18.63 Q2 '22: -595.10 Q4 '23: 0.05 Q1 '24: 1.74 Q2 '24: 7.17 Q3 '24: 7.05 Q4 '24: -0.11 Q1 '25: 0.05 Q2 '25: 0.04 Q3 '25: 0.05 Q4 '25: 0.00 Q1 '26: -0.04 Q2 '26: -0.11 Q2 '16 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.